Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, D.H. | - |
dc.contributor.author | Park, H.J. | - |
dc.contributor.author | Jang, H.H. | - |
dc.contributor.author | Kim, S.-H. | - |
dc.contributor.author | Jung, Y. | - |
dc.contributor.author | Lee, W.-S. | - |
dc.date.available | 2020-08-27T09:35:17Z | - |
dc.date.created | 2020-08-14 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 0735-7907 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78058 | - |
dc.description.abstract | Background: Programmed death 1 (PD-1) and its ligand PD-L1 play a key dysfunction of T lymphocytes. The purpose of this study was to assess and compare the prognostic role of tumor- TILs and its relationship with PD-L1 expression in stage II and III colon cancer. Methods: Immunohistochemisty was used to assess the densities of CD8+, CD4+, and FOXP3+ cells, and PD-L1 expression in intraepithelial tumor site from 58 stage II and III colon cancers. These were evaluated for association with histopathologic features and overall survival. Results: PD-L1-positive tumors contained a higher number of CD8+ TILs with statistical significance (p = 0.001). CD4+ TILs showed positive correlation with PD-L1 expression (p = 0.034). There were no associations between PD-L1 expression and FOXP3+ TILs. Microsatellite instability (MSI)-high status (p = 0.001; Odd ration 18.0; 95% CI = 4.3–74.8) was the strongest prognostic factor along with mucinous/poor cell differentiation, CD8 and right tumor location was associated with PD-L1 expression (p = 0.024, 0.035 and 0.033, respectively). Conclusion: This study demonstrated that PD-L1 expression was associated with MSI-high, increased CD8+ TILs, mucinous and poor cell differentiation, and right-sided tumor location. © 2020 The Author(s). Published by Taylor & Francis Group, LLC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Taylor and Francis Ltd | - |
dc.relation.isPartOf | Cancer Investigation | - |
dc.title | Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000556485300001 | - |
dc.identifier.doi | 10.1080/07357907.2020.1793349 | - |
dc.identifier.bibliographicCitation | Cancer Investigation, v.38, no.7, pp.406 - 414 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85089173661 | - |
dc.citation.endPage | 414 | - |
dc.citation.startPage | 406 | - |
dc.citation.title | Cancer Investigation | - |
dc.citation.volume | 38 | - |
dc.citation.number | 7 | - |
dc.contributor.affiliatedAuthor | Jung, D.H. | - |
dc.contributor.affiliatedAuthor | Park, H.J. | - |
dc.contributor.affiliatedAuthor | Jang, H.H. | - |
dc.contributor.affiliatedAuthor | Kim, S.-H. | - |
dc.contributor.affiliatedAuthor | Jung, Y. | - |
dc.contributor.affiliatedAuthor | Lee, W.-S. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | biochemical markers | - |
dc.subject.keywordAuthor | Cancer biomarkers | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.